FDA denies Amarin's ANCHOR SPA appeal

|About: Amarin Corporation PLC (AMRN)|By:, SA News Editor

The FDA has not accepted Amarin's (AMRN) appeal regarding the rescission of the SPA for Vascepa's ANCHOR study.

The company also says its "request for a meeting at a high level within the FDA regarding the appeal was not granted."

AMRN says it plans to continue to pursue the appeal. (8-K)

AMRN -12% premarket